Satellite Symposia Agenda

Satellite Symposium MSD | Redefining discussions in the management of melanoma patients

Wednesday, April 24th 2019 | 16:30 - 17:30 | AMPHITHEATRE LAVOISIER - Level 1


Chairs: Caroline ROBERT (France), Peter MOHR (Germany)

 

 

Satellite Symposium BRISTOL-MYERS SQUIBB | Perspectives on melanoma: present challenges and future considerations

Thursday, April 25th 2019 | 13:00 - 14:00 | AMPHITHEATRE LAVOISIER - Level 1


Chair: Caroline ROBERT (France)

 

 

Satellite Symposium NOVARTIS | Targeted adjuvant therapy in melanoma, COMBIning our knowledge on cure-rate models and treatment-related decisions


Thursday, April 25th 2019 | 15:00 - 16:00 | PETIT AMPHITHEATRE - Level 0


Chair: Céleste LEBBE (France)

 

Satellite Symposium HELSINN / RECORDATI RARE DISEASES | Chlormethine gel and MF-CTCL: exploring the real-world evidence

Thursday, April 25th 2019 | 18:00 - 19:00 | AMPHITHEATRE LAVOISIER - Level 1


Chairs: Martine BAGOT (France), Ellen J. KIM (USA)

 

Satellite Symposium PIERRE FABRE | Patients’ cases in the evolving landscape of BRAF-mutant metastatic melanoma


Friday, April 26th 2019 | 13:00 - 14:00 | AMPHITHEATRE LAVOISIER - Level 1


Chairs: Céleste LEBBE (France), Axel HAUSCHILD (Germany)

 

 

Satellite Symposium ROCHE | Building on experience: optimising treatment outcomes for patients with advanced basal cell carcinoma

 

Friday, April 26th 2019 | 15:30 - 16:30 | PETIT AMPHITHEATRE - Level 0

 

Chair: Nicole BASSET-SÉGUIN (France)

 

 

Satellite Symposium SANOFI GENZYME/REGENERON | Managing Advanced CSCC in 2019: Cases & Conversations


Friday, April 26th 2019 | 15:30 - 16:30 | AMPHITHEATRE LAVOISIER - Level 1
 

Chair: Céleste LEBBE (France)

By continuing to browse this website, you accept cookies which are used to offer a personalized experience on our website, generate statistics and realize advertising or social network tracking. Find out more about our Privacy & Cookie policy and how to manage them on your browser. You can change your cookie settings at any time.

Ok Read more